AU2012275346B2 - Predictive biomarker of survival in the treatment of renal cell carcinoma - Google Patents

Predictive biomarker of survival in the treatment of renal cell carcinoma Download PDF

Info

Publication number
AU2012275346B2
AU2012275346B2 AU2012275346A AU2012275346A AU2012275346B2 AU 2012275346 B2 AU2012275346 B2 AU 2012275346B2 AU 2012275346 A AU2012275346 A AU 2012275346A AU 2012275346 A AU2012275346 A AU 2012275346A AU 2012275346 B2 AU2012275346 B2 AU 2012275346B2
Authority
AU
Australia
Prior art keywords
inhibitor
ang2
plgf
vegfr
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012275346A
Other languages
English (en)
Other versions
AU2012275346A1 (en
Inventor
Abraham Antonio Anderson
David M. Weinreich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2012275346A1 publication Critical patent/AU2012275346A1/en
Application granted granted Critical
Publication of AU2012275346B2 publication Critical patent/AU2012275346B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2012275346A 2011-06-29 2012-06-28 Predictive biomarker of survival in the treatment of renal cell carcinoma Active AU2012275346B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161502686P 2011-06-29 2011-06-29
US61/502,686 2011-06-29
PCT/US2012/044673 WO2013003606A1 (en) 2011-06-29 2012-06-28 Predictive biomarker of survival in the treatment of renal cell carcinoma

Publications (2)

Publication Number Publication Date
AU2012275346A1 AU2012275346A1 (en) 2013-12-19
AU2012275346B2 true AU2012275346B2 (en) 2016-03-17

Family

ID=46545468

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012275346A Active AU2012275346B2 (en) 2011-06-29 2012-06-28 Predictive biomarker of survival in the treatment of renal cell carcinoma

Country Status (7)

Country Link
US (1) US9151761B2 (https=)
EP (1) EP2726088B1 (https=)
JP (1) JP6069312B2 (https=)
AU (1) AU2012275346B2 (https=)
CA (1) CA2840212A1 (https=)
MX (1) MX358726B (https=)
WO (1) WO2013003606A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
AU2015345323A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
CA2963606A1 (en) * 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use
WO2016209972A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
WO2017110764A1 (ja) * 2015-12-24 2017-06-29 公益財団法人がん研究会 マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー
JP6942135B2 (ja) * 2016-01-25 2021-09-29 サノフイＳａｎｏｆｉ 血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089445A2 (en) * 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5871723A (en) 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CA2633211A1 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2089425B1 (en) 2006-11-10 2011-08-17 CovX Technologies Ireland Limited Anti-angiogenic compounds
WO2008115714A2 (en) * 2007-03-20 2008-09-25 Apocell, Inc. Evaluating rtk target drugs
EP2288383A1 (en) * 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089445A2 (en) * 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DePRIMO, S.E. et al. J Transl Med. 2007; 5: 32. Published online 2007 Jul 2. *
MOTZER, R.J. et al. J Clin Oncol. 2006 Jan 1;24(1):16-24. Epub 2005 Dec 5. *
NCT00467025 Clinical Trial by Amgen: "AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib", ClinicalTrials.gov website, 26 April 2007. Retrieved from the internet: https://clinicaltrials.gov on the 11 May 2015. *
RINI, B.I. "Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma." J Clin Oncol. 2008 Aug 1;26(22):3743-8. *

Also Published As

Publication number Publication date
EP2726088B1 (en) 2019-01-02
MX358726B (es) 2018-09-03
AU2012275346A1 (en) 2013-12-19
US9151761B2 (en) 2015-10-06
CA2840212A1 (en) 2013-01-03
JP2014521070A (ja) 2014-08-25
EP2726088A1 (en) 2014-05-07
US20140348824A1 (en) 2014-11-27
WO2013003606A1 (en) 2013-01-03
MX2013015146A (es) 2014-03-27
JP6069312B2 (ja) 2017-02-01

Similar Documents

Publication Publication Date Title
AU2012275346B2 (en) Predictive biomarker of survival in the treatment of renal cell carcinoma
CA2853836C (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
JP2019048896A (ja) ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用
JP2002525104A (ja) Ｔｉｅ２アゴニスト抗体
JP2016006101A (ja) Ｄｌｌ４アンタゴニスト及び化学療法剤を用いたがんの治療方法
US10106601B2 (en) Inhibition of PLGF to treat philadelphia chromosome positive leukemia
US9599620B2 (en) Methods and monitoring of treatment with a DLL4 antagonist
KR20140030153A (ko) 항-인테그린을 사용하여 항혈관 형성 요법을 개선하기 위한 방법 및 조성물
US20190004048A1 (en) Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
AU2011252841B2 (en) Enhanced death receptor agonists
EP3440111B1 (en) Anti-vegfr-1 antibodies and uses thereof
AU2004290016A1 (en) Monkey immunoglobulin sequences
TW202430209A (zh) 單獨使用雙特異性EGFR x CD28抗體或其與抗PD-1抗體組合使用治療癌症之方法
US11872282B2 (en) Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
US20120183546A1 (en) Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
Chakrabarti et al. Current protein-based anti-angiogenic therapeutics
US20250018010A1 (en) Pharmaceutical composition
US20210009672A1 (en) Methods of treating or preventing liver fibrosis with inhibition of activins a &amp; b
CN120418281A (zh) 靶向PD-L1和中和Gas6之融合蛋白及其用途
MXPA06004910A (en) Monkey immunoglobulin sequences

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)